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Abstract
Background: Esophageal adenocarcinoma (EAC) accounts for an estimated 15 690 deaths in the US each
year. The 5-year mortality is 80% unless the disease is caught early. Barrett’s esophagus (BE) is the primary risk
for developing EAC, therefore, the best method for early detection is identification of patients with BE. In
addition, recent advances in the treatment of high-grade dysplasia and early esophageal carcinoma have
provided safe effective alternatives to esophagectomy. Endoscopy is the current standard to screen patients
with BE. This method is cost prohibitive, invasive, and requires specialty training making it unfit as a tool for
screening at risk populations. The Cytosponge coupled with trefoil factor 3 (TFF3) is a novel diagnostic test
used in identifying Barrett’s esophagus. Is the Cytosponge coupled with TFF3 expression an effective method
to diagnose patients with Barrett’s esophagus in comparison to endoscopy with biopsy?
Methods: An exhaustive literature search using MEDLINE-Ovid, Web of Science, and Evidence Based
Medical Review Multifile was conducted. The keywords used in the search included: “Barrett’s esophagus”
and “Cytosponge.” Search results were subsequently scanned and eligibility criteria were applied. Studies were
included if they directly compared the efficacy of Cytosponge coupled with TFF3 to endoscopy with biopsy.
Other inclusion criteria required the studies to include human subjects and be in the English language. Studies
were evaluated for quality using GRADE criteria.
Results: A total of 13 studies were screened. After duplicates were removed and eligibility criteria were
applied, two studies remained and are contained in this systematic review. One study included 504
participants and was a prospective cohort design. The second study was a multi-center case-control design and
included 1110 participants. Both studies evaluated the sensitivity and specificity of the Cytopsonge-TFF3.
One study demonstrated the sensitivity and specificity to be about 80% and 92% respectively.
Conclusion: In conclusion, the Cytosponge-TFF3 possesses significant potential in its ability to be used as a
cost effective, patient accepted, and accurate method for screening primary care populations for Barrett’s
esophagus. Further clinical studies will be needed to determine the applicability and accuracy of the
Cytosponge across primary care populations. Furthermore, additional steps need to be taken to improve the
sensitivity of the Cytosponge, such as improvements related to bettering the reliability of specimen collection.
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Abstract  
Background: Esophageal adenocarcinoma (EAC) accounts for an estimated 15 690 deaths in the 
US each year. The 5-year mortality is 80% unless the disease is caught early. Barrett’s esophagus 
(BE) is the primary risk for developing EAC, therefore, the best method for early detection is 
identification of patients with BE. In addition, recent advances in the treatment of high-grade 
dysplasia and early esophageal carcinoma have provided safe effective alternatives to 
esophagectomy. Endoscopy is the current standard to screen patients with BE. This method is 
cost prohibitive, invasive, and requires specialty training making it unfit as a tool for screening at 
risk populations. The Cytosponge coupled with trefoil factor 3 (TFF3) is a novel diagnostic test 
used in identifying Barrett’s esophagus. Is the Cytosponge coupled with TFF3 expression an 
effective method to diagnose patients with Barrett’s esophagus in comparison to endoscopy with 
biopsy?  
Methods: An exhaustive literature search using MEDLINE-Ovid, Web of Science, and Evidence 
Based Medical Review Multifile was conducted. The keywords used in the search included: 
“Barrett’s esophagus” and “Cytosponge.” Search results were subsequently scanned and 
eligibility criteria were applied. Studies were included if they directly compared the efficacy of 
Cytosponge coupled with TFF3 to endoscopy with biopsy. Other inclusion criteria required the 
studies to include human subjects and be in the English language. Studies were evaluated for 
quality using GRADE criteria. 
Results:  A total of 13 studies were screened. After duplicates were removed and eligibility 
criteria were applied, two studies remained and are contained in this systematic review. One 
study included 504 participants and was a prospective cohort design. The second study was a 
multi-center case-control design and included 1110 participants. Both studies evaluated the 
sensitivity and specificity of the Cytopsonge-TFF3. One study demonstrated the sensitivity and 
specificity to be about 80% and 92% respectively.  
Conclusion: In conclusion, the Cytosponge-TFF3 possesses significant potential in its ability to 
be used as a cost effective, patient accepted, and accurate method for screening primary care 
populations for Barrett’s esophagus. Further clinical studies will be needed to determine the 
applicability and accuracy of the Cytosponge across primary care populations. Furthermore, 
additional steps need to be taken to improve the sensitivity of the Cytosponge, such as 
improvements related to bettering the reliability of specimen collection. 
Keywords: Cytosponge, Barrett’s esophagus 
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 Screening Patients for Barrett’s Esophagus with Cytosponge Coupled with 
Trefoil Factor 3 Expression Compared to Endoscopy 
Background 
An estimated 16 910 people in the US are diagnosed with esophageal adenocarcinoma 
each year and 15 690 deaths occur in the same time frame.1 Esophageal adenocarcinoma (EAC) 
is a particularly aggressive and deadly cancer with a 5 year mortality of 80%, which is in part 
due to late detection of the disease.2,3 Barrett’s esophagus is the primary risk factor for the 
development of EAC, making surveillance of these patients of the utmost importance. While 
traditional methods for treatment EAC have been invasive and wrought with complications, 
recent improvements in the treatment of esophageal cancer have further fueled the need for early 
detection of at risk populations. 
Barrett’s esophagus (BE) represents a metaplastic change in the mucosal tissue located at 
the esophagogastric junction. Studies vary widely in their estimation of the prevalence of the BE 
in the general population, but one study4 estimates 6.8% of people in the US have BE. Another 
study5 estimated a prevalence of 1.6%. Even the more conservative estimate of 1.6% would 
translate into 3.3 million people in the US having BE.5 Patients with frequent or severe acid 
reflux are at increased risk for developing BE; therefore, these patients are the targeted 
population for whom improved detection would most benefit.6  
Patients with Barrett’s esophagus have a 0.5% per year risk of conversion to esophageal 
adenocarcinoma according to a systematic review and meta-analysis.7 Although esophageal 
adenocarcinoma carries a high mortality, early detection and treatment has been shown to 
significantly increase the rate of survival to > 80% for superficial carcinomas.8 Esophagectomy 
has traditionally been the curative treatment even in early asymptomatic disease. While this 
treatment has been shown to be effective, it carries risks for significant morbidity and mortality. 
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 In recent years development of less invasive esophageal sparing procedures has shown 
promise with improvements in safety while maintaining efficacy. Such procedures include 
endoscopic mucosal resection and radiofrequency ablation. These procedures have shown 
promise in decreasing the risk of morbidity and mortality related to the treatment of high-grade 
dysplasia and early esophageal carcinomas. A meta-analysis of endoscopic submucosal 
dissection of early esophageal carcinoma showed a 99% resection rate and low incidence of 
complications.9,10  
 With the advent of less invasive endoscopic treatments, detection of Barrett’s esophagus 
across larger populations has become even more crucial. The current standard for diagnosis is 
through direct esophageal visualization via endoscopy coupled with biopsy, which requires 
expertise to perform, is commonly done under anesthesia, is expensive, and is invasive in 
nature.11 Therefore, endoscopy is unfit for systematic screening of Barrett’s esophagus across a 
large population. For these reasons, a cheap, easy to administer, safe, accurate, and acceptable 
screening method should be more extensively explored.  
 Cytosponge coupled with trefoil factor 3 (TFF3) immunocytochemistry has shown 
promise in its ability to detect Barrett’s esophagus in a cheap, easy to administer fashion. This 
device consists of a 3cm diameter spherical mesh contained within a 2cm gelatin capsule 
attached to a retrieval string. The patient is instructed to swallow the capsule containing the 
mesh, which dissolves upon reaching the stomach releasing the spherical mesh. With the mesh 
deployed the patient manually pulls the string, attached to the mesh, up and out through their 
mouth. As the mesh is pulled through the esophagus it collects esophageal cells. At which point 
the cells are analyzed via immunohistochemical staining for the biomarker, trefoil factor 3. TFF3 
expression has been extensively studied and has been shown to be a distinguishing characteristic 
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in the cellular transformation related to BE. Therefore, TFF3 expression distinguishes BE cells 
from normal gastric and esophageal cells.12 Is Cytosponge coupled with trefoil factor 3 
expression an effective method to diagnose patients with Barrett’s esophagus in comparison to 
endoscopy with biopsy? 
Methods 
 An exhaustive literature search using MEDLINE-Ovid, Web of Science, and Evidence 
Based Medical Review Multifile was conducted. The keywords used in the search included: 
“Barrett’s esophagus” and “Cytosponge.” Search results were subsequently scanned and 
eligibility criteria were applied. Studies were included if they directly compared the efficacy of 
Cytosponge coupled with TFF3 to endoscopy with biopsy. Other inclusion criteria required the 
studies to include human subjects and be in the English language. Studies were evaluated for 
quality using GRADE criteria.17 
Results  
 An initial search resulted in 13 articles for review. Upon elimination of duplicates and 
application of eligibility criteria, there were a total of two articles that met the standards for this 
study. One study14 was a prospective cohort design while the other study15 was a multi-center 
case-control design. Both studies determined the sensitivity and specificity of Cytosponge 
coupled with TFF3 compared to endoscopy with biopsy. See Table I. 
Kadri et al 
 This study14 was a prospective cohort study design. Researchers set out to determine 
whether Cytosponge would be widely accepted by the patient population as well as its ability to 
accurately identify the presence of Barrett’s esophagus compared to endoscopy with biopsy. The 
study took place in the UK across 12 general practices. Patients were asked to perform the 
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Cytosponge test and then were invited to undergo endoscopy. Patients were also asked to 
complete questionnaires regarding their sociodemographics, anxiety (as related to the tests), and 
visual analogue scales to determine test acceptability.14   
 Eligible patients were identified by searching the prescribing databases of 12 primary 
care practices for patients 50-70 years old, who have had a prescription for an acid suppressant 
for more than a 3-month period, within the last 5 years. Exclusion criteria were a previous 
diagnosis of Barrett’s esophagus, endoscopy within the past year, dysphagia, known portal 
hypertension, drug or pathophysiologic abnormality of coagulation, important physical or 
psychological comorbidity precluding endoscopy, or inability to provide informed consent. 
General practices then sent eligible patients an invitation letter. Recruitment of patients 
continued until 500 people were included in the study.14   
 Following enrollment, either a research nurse or research fellow administered the test. 
Within 30 minutes following the test patients were asked to complete an anxiety inventory, 
impact of event scale, and visual analogue to measure acceptability. Two independent 
pathologists carried out immunostaining for trefoil factor 3, and results were reported in a binary 
fashion as being either positive or negative. The Cohen’s kappa coefficient of the two scorers 
was 0.74.14  
 Participants who successfully swallowed the Cytosponge were invited to undergo 
endoscopy within 3 weeks of the original test. All endoscopists were instructed to strictly adhere 
to the agreed upon Prague C&M criteria for diagnosis of BE. Barrett’s esophagus was defined as 
“endoscopically visible columnar lined epithelium arising at least 1cm circumferentially above 
the gastro-esophageal junction with intestinal metaplasia.” Endoscopists and pathologists were 
blinded to the results of the Cytosponge test.14  
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 Overall 2696 patients were identified as being eligible and were invited to participate. 
504 patients were originally enrolled in the study of which 501 were able to successfully 
swallow the Cytosponge. Two Cytosponges did not properly deploy and 32 participants failed to 
undergo endoscopy.  Patients who did not complete the endoscopy were considered to not have 
Barrett’s esophagus. No adverse events were associated with swallowing the Cytosponge. 
According to endoscopy 3.0% (15/501) were diagnosed with Barrett’s esophagus containing 
segments of circumferential length 1 cm or greater, while 2.2% (10/501) of patients were 
diagnosed with segments of 2 cm or greater.14   
 The Cytosponge had a sensitivity and specificity of 73.3% (95% CI 44.9%-92.2%) and 
93.8% (95% CI 91.3%-95.8%) respectively in patients containing segments of Barrett’s 
esophagus ≥1cm in length. The sensitivity and specificity increased to 90% (95% CI 55.5%-
99.7%) and 93.5% (95% CI 90.9%-95.5%) in patients containing segments of BE that were 
≥2cm in length. The positive predictive value was 26.8% and a negative predictive value of 
99.1%. Response rates to questionnaires were high and showed a low level of anxiety in most 
patients before and after the tests.14   
 The authors noted that this study was not designed in a manner to ascertain the accuracy 
of the Cytosponge test to a high degree of precision as evidenced by the wide confidence interval 
for the estimates of sensitivity. From this study it was concluded that the Cytosponge-TFF3 has 
shown to be promising as a screening tool for Barrett’s esophagus both in patient acceptability 
and high negative predictive value. The test has proven to be both safe and acceptable in a 
primary care setting. Although these results are promising, the authors concluded that more 
studies are needed to further evaluate the precision of the Cytosponge test.14  
Ross-Innes et al 
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 This study15 was a multi-center case-control study aimed at precisely determining the 
sensitivity and specificity of the Cytopsponge coupled with TFF3 compared to endoscopy with 
biopsy. The primary outcomes were sensitivity, specificity, safety, and acceptability of the 
Cytosponge-TFF3. Secondary endpoints were sensitivity of the Cytosponge-TFF3 in patients 
with dysplasia and in patients who swallowed the Cytopsonge on two occasions.15  
 Patients who were scheduled to have an endoscopy performed for a clinically indicated 
reason were recruited to participate in the study. Patients who had a previously determined 
diagnosis of Barrett’s esophagus were allocated to be in the case arm of the study. On the other 
hand, patients who were referred to endoscopy for dyspepsia or reflux symptoms and did not 
have a previous diagnosis of Barrett’s esophagus were allocated to be in the control arm of the 
study. Patients who were subsequently diagnosed with Barrett’s esophagus by endoscopy in 
accordance with the Prague C&M criteria were crossed over to the case arm of the study.15  
 Over the course of a single visit participants completed questionnaires regarding 
demographics, exposures, and symptoms along with the Cytosponge test and an endoscopy with 
biopsy. Patients who happen to undergo a second endoscopy during the course of the study were 
invited to undergo a second Cytosponge test as well. In addition four tertiary referral centers 
were used to enrich the study with patients who were shown to have dysplasia.15 
 Cytosponge samples were anonymized, processed, and scored in a binary fashion as 
either positive or negative. The scorers were one of two independent researchers and a 
gastrointestinal histo-cytopathologist. The scorers were blinded to the clinical diagnosis of each 
patient.15  
 Endoscopies were performed within an hour of the Cytosponge test. Biopsies were taken 
from the cardia as well as 2 cm above the squamocolumar junction in all patients while those 
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with Barrett’s esophagus also had additional biopsies taken in accordance with the Seattle 
surveillance protocol.  The biopsies were reviewed by histo-cytopathologists who were blinded 
to the results of the Cytosponge test.15  
 A total of 1110 patients were enrolled in this study. There were 463 participants  who 
were allocated as the controls and 647 patients with Barrett’s esophagus who were allocated to 
the cases arm of the study. Three adverse events were reported although; none were connected 
with the Cytosponge. One patient had onset of atrial fibrillation, one patient was admitted for 
bleeding from a biopsy site, and one patient was found to have unsuspected esophageal varices 
without evidence of bleeding. On endoscopy16.7% of patients had oozing of blood following the 
Cytosponge test, but did not require intervention.15  
 A total of 93.9% (1042/1110) of patients successfully swallowed the Cytosponge. The 
overall sensitivity and specificity of the Cytosponge was 79.9% (95% CI 76.4%-83.0%, 
p<0.001) and 92.4% (95% CI 89.5%-94.7%) respectively. Sensitivity of the Cytosponge 
increased to 87.2% (95% CI 83.0%-90.6%) in patients with segments of Barrett’s esophagus ≥3 
cm in length. Patients who swallowed the Cytosponge twice during the course of the study had a 
sensitivity of 89.7% (95% CI 82.3%-94.8%). The positive and negative predictive values were 
determined to be 34.7% and 98.9% respectively. The median value, given by patients, on the 
visual analogue scale was 6 out of 10. A score of 0 representing the worst experience ever and 10 
being the best experience ever.15  
 The authors pointed out that 76% of Cytosponge tests resulting in a false negative were 
found to be due to the absence of columnar cells on the specimen rather than failure of the TFF3.  
As a result, the authors concluded that patients with a negative result and few to no columnar 
cells on the specimen should have a repeated test to ensure adequate sampling, if the test were 
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applied clinically. Other proposed alternatives to potentially improve sensitivity were to have all 
patients swallow the sponge twice or engineer the sponge to have improved cellular collection. 
Although this study was designed to precisely determine the accuracy of the Cytosponge, the 
data cannot be applied to a primary care population due to the case-control design.15  
 The authors concluded that the Cytosponge-TFF3 can diagnose Barrett’s esophagus in an 
acceptable accurate manner. Furthermore, the Cytosponge has shown promise in its potential to 
be used as a screening tool for patients with reflux symptoms.15  
Discussion  
 After analyzing the data from these two studies14,15 the Cytosponge has proven to be both 
widely acceptable to patients and effective in diagnosing Barrett’s esophagus, as demonstrated 
with high negative predictive values and reasonable sensitivity values (see Table II). The 
Cytosponge offers a method for developing a more robust screening strategy regarding Barrett’s 
esophagus. Early detection in conjunction with treatment of esophageal adenocarcinoma has 
been shown to vastly improve the survival rate of patients.2,3 With Barrett’s esophagus being the 
greatest risk factor for developing esophageal adenocarcinoma, a need for screening at risk 
populations is clearly present.6 Endoscopy has proven to be cost prohibitive and requires 
excessive resources to be an adequate screening tool to be applied in a generalized manner across 
primary care populations.  
One particular model estimated that screening all white males >50 years old via 
endoscopy would cost $10 440 per quality adjusted life year saved.11 Therefore, a cost effective, 
accurate, and acceptable test is needed for screening primary care populations in order to 
improve early detection of Barrett’s esophagus. The Cytosponge has been shown to be a much 
cheaper, estimated to be $152 per test, as compared with endoscopy, estimated to cost $785 per 
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test respectively.13 Furthermore, the Cytosponge has proven to be safe by the first study 
reviewed,14 finding no adverse complications and the second study reviewed,15 only finding 
minor esophageal abrasions none of which needed intervention. Ease of administration has 
proven to be yet another benefit of the Cytosponge requiring only about 10 minutes for specimen 
collection and being a procedure performed by research nurses.  
 Although the Cytosponge has shown to be imperfect with sensitivities ranging from 
73.3% to 90% depending on the segment length of BE and the number of times the patient 
swallowed the sponge, there is promise in its acceptability, ease of application, and low cost (see 
Table II).13-15 The sensitivity and specificity of the Cytosponge are comparable with screening 
tests currently being used such as mammography.16 Simple improvements, such as, repeating the 
test in cases where few to no columnar cells were collected, have the potential to improve the 
sensitivity of the Cytosponge.15  
 These studies14,15 were limited in their design requiring further evaluation through blind 
comparisons to endoscopy and biopsy which is the gold standard in order to generalize the data 
to a primary care population. The two articles used in this study were assessed for quality of 
evidence by making use of the GRADE criteria.17 Through careful consideration of these studies 
it was determined that there exists the potential for publication bias within both of these studies 
given possible conflicts of interest from companies involved with funding this research and their 
potential to profit from this technology.14,15 Even though the potential for publication bias exists, 
it is not likely, due to the objective design of these studies. Overall, no downgrades were applied 
to these studies through the assessment of their quality of evidence. An overall quality of 
evidence was rated as being “low,” which is inherent to the prospective cohort and case-control 
study designs. 
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Moving forward researchers have several areas of interest that need further evaluation. 
Potential for improved sensitivity through advances in engineering or altering testing procedures 
is of future interest. Clinical trials are also needed in order to evaluate the applicability and 
accuracy of this technology in any wide spread manner.  
Conclusion 
 In conclusion, the Cytosponge-TFF3 has been shown to possess significant potential in 
its ability to be used as a cost-effective, patient accepted, and accurate method for screening 
primary care populations for Barrett’s esophagus (see Table II). The results of these two studies 
are compelling for the utilization of the Cytosponge-TFF3 to screen populations of patients at 
risk for Barrett’s esophagus within a primary care setting. Further clinical studies will be needed 
to definitively determine the applicability and accuracy of the Cytosponge-TFF3 in its 
administration across primary care populations. Furthermore, additional steps need to be taken to 
improve the sensitivity of the Cytosponge, specifically improvements related to bettering the 
reliability of specimen collection. With these proposed improvements and pending further study, 
the Cytosponge-TFF3 possesses the capability to accurately, cheaply, and safely screen patients 
potentially leading to improved early detection and treatment of esophageal adenocarcinoma.  
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Table I. Characteristics of Reviewed Studies, GRADE profile 
 
Study Study 
Design  
Downgrade Criteria Upgrade 
Criteria 
Quality  
Limitations Indirectness Imprecision Inconsistency Publication 
Bias 
Kadri et al Prospective 
Cohort 
Not Serious  Not Serious Not Serious Not Serious Not likely None Low 
Ross-Innes 
et al 
Case-
control 
Not Serious Not Serious Not Serious Not Serious Not likely None Low 
GRADE: Grading of Recommendations, Assessments, Development and Evaluation. 
 
Table II. Sensitivity of the Cytosponge-TFF3 in different groups of patients (Ross-Innes et al 14 ) 
 
Patients Total Number Sensitivity (95% CI) 
All BE patients (≥C1 or M3)  596 79.9% (76.45-83.0%) 
Segment Length 
≥C1 533 79.5% (75.9%-82.9% 
≥C2 416 83.9% (80.0%-87.3%) 
≥C3 320 87.2% (83.0-90.6%) 
Indefinite for Dysplasia  46 73.9% (58.9%-85.7%) 
HGD/IMC 101 84.2% (75.6%-90.7%) 
Patients having two 
Cytosponge Tests  
107 89.7% (82.3%-94.8%) 
C; Circumferential length, M; Maximal length, IMC; Intramucosal carcinoma, BE; Barrett’s esophagus 
 
 
 
